Physiology Research Center, Iran University of Medical Sciences, Tehran, Iran; Department of Physiology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Physiology Research Center, Iran University of Medical Sciences, Tehran, Iran; Department of Physiology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.
J Chem Neuroanat. 2021 Mar;112:101886. doi: 10.1016/j.jchemneu.2020.101886. Epub 2020 Nov 12.
It has been reported that apelin-13 possesses neuroprotective effects against cerebral ischemia/reperfusion injury (IRI). Disabilities in sense, movement and balance are the major stroke complications which, result in a high rate of mortality. Here, effects of intravenous (IV) injection of apelin-13 on the severity of neural death, infarct volume, neurological defects and its association with nitric oxide (NO) were investigated. A rat model of cerebral IRI was created by middle cerebral artery occlusion (MCAO) for 60 min and restoration of blood flow for 23 h. Animals were randomly assigned into six groups: sham, ischemia (MCAO), vehicle (MCAO + PBS) and three treatment groups (MCAO + apelin-13 in 10, 20, 40 μg/kg doses, IV). All injections were carried out via tail vein injection 5 min before reperfusion. Neural loss and infarct volume were evaluated by Nissl and 2,3,5-triphenyltetrazolium chloride (TTC) staining, respectively. Neurological defects were scored by standard modified criteria. Serum NO was measured by colorimetric method. Apelin-13 in doses of 20 and 40 μg/kg significantly reduced neural death, infarct volume and disturbance of sensory-motor balance compared to control and vehicle groups (p < 0.05). Serum NO levels reduced in MCAO groups compared to sham. Apelin-13 restored serum NO levels at 20 μg/kg dose (p < 0.05). Our data showed beneficial effect of IV injection of apelin-13 on sensory-motor balance defects by reducing neural death and restoration of serum NO levels. The present study shows the validity of apelin-13 in treatment of ischemic stroke in different administration methods.
据报道，apelin-13 对脑缺血/再灌注损伤（IRI）具有神经保护作用。感觉、运动和平衡障碍是中风的主要并发症，导致高死亡率。在这里，研究了静脉（IV）注射 apelin-13 对神经死亡严重程度、梗死体积、神经缺陷及其与一氧化氮（NO）的关系。通过大脑中动脉闭塞（MCAO）60 分钟和血流恢复 23 小时创建了大鼠脑 IRI 模型。动物被随机分为六组：假手术组、缺血组（MCAO）、载体组（MCAO+PBS）和三组治疗组（MCAO+apelin-13 10、20、40μg/kg 剂量，IV）。所有注射均在再灌注前 5 分钟通过尾静脉注射进行。通过尼氏染色和 2,3,5-三苯基氯化四氮唑（TTC）染色评估神经损失和梗死体积。通过标准改良标准对神经缺陷进行评分。通过比色法测量血清 NO。与对照组和载体组相比，20 和 40μg/kg 的 apelin-13 剂量显著降低了神经死亡、梗死体积和感觉-运动平衡障碍（p<0.05）。与假手术组相比，MCAO 组的血清 NO 水平降低。Apelin-13 在 20μg/kg 剂量时恢复血清 NO 水平（p<0.05）。我们的数据表明，IV 注射 apelin-13 通过减少神经死亡和恢复血清 NO 水平对感觉-运动平衡缺陷具有有益作用。本研究表明不同给药方式 apelin-13 在治疗缺血性中风中的有效性。
